Abstract:OBJECTIVE For the past few years,the checkpoint inhibitors,such as PD-1 inhibitors and CTLA-4 in-hibitors,demonstrated an advantage in terms of the survival of melanoma and lung cancer patients with the development of novel immunotherapy agents.Thus,exploring predictive biomarkers may contribute to the screening the target population for immune checkpoint inhibitors and promoting the development of individualized precision therapy in advanced cancer. This article induced the progress about the predictive biomarkers of checkpoint inhibitors,providing a theoretical basis for the precision medicine study of immunotherapy.METHODS Based on Pubmed and CNKI database,by using "immune checkpoint inhibitors,biomarker,prognosis"as key words to trace related papers from 1995-10 to 2017-02.Inclusion crite-ria were as follows:the definition of immune checkpoint inhibitors;the mechanism of immune checkpoint inhibitors;the predictive factors of immune checkpoint inhibitors.Exclusion criteria:(1)Those exists problems in research designs or sta-tistical methods.(2)those has incomplete data or unclear results.Totally 44 papers (2 chinese literatures)were finally in-cluded for analysis.RESULTS The immune checkpoint inhibitors work specifically on the body's immune system to en-hance the antitumor activity of various immune cells.It is relatively slower to take effects.However,once the effects ap-pear,it will last for a very long period.Selecting the appropriate predictive factors and screening the target population be-fore the treatment plays a very important role for clinical choice.It has been proved that the expression rate of PD-L1,mi-crosatellite instability and tumor mutation burden are correlated with the treatment effects of immune checkpoint inhibi-tors.The significance of other biomarkers need further investigation.CONCLUSION The expression rate of PD-L1, microsatellite instability and tumor mutation burden were reliable predictive biomarkers for the treatment effects of im-mune checkpoint inhibitors.

Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy

Predictive biomarkers for checkpoint blockade-based immunotherapy

Predictive Biomarkers for Tumor Immune Checkpoint Blockade

Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition

Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade

Research progress and clinical application of predictive biomarker for immune checkpoint inhibitors

Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy

Lessons Learned from the Blockade of Immune Checkpoints in Cancer Immunotherapy

CD69 and SBK1 as potential predictors of responses to PD-1/PD-L1 blockade cancer immunotherapy in lung cancer and melanoma

Research progress of anti-PD-1 / PD-L1 immunotherapy biomarkers

Progresses in biomarkers for cancer immunotherapy

Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies

Immune checkpoint inhibitors: recent progress and potential biomarkers

Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy

FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients

Rational Discovery of Response Biomarkers: Candidate Prognostic Factors and Biomarkers for Checkpoint Inhibitor-Based Immunotherapy.

Predictive Biomarkers for Cancer Immunotherapy with Immune Checkpoint Inhibitors

Predictive markers of immune checkpoint inhibitors

Predicting patient outcomes after treatment with immune checkpoint blockade: A review of biomarkers derived from diverse data modalities

Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.

Advances and prospects of biomarkers for immune checkpoint inhibitors